Novavax Stock Is Too Sickly To Buy

InvestorPlace2022-05-10

Novavax’s Covid-19 vaccine still isn’t approved for use in the U.S.With the pandemic in full retreat and the majority of people now fully vaccinated, demand for Novavax’s vaccine is likely to be weak....

Source Link
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

  • Gee1
    2022-05-10
    Gee1
    good
  • LuckyPiggie
    2022-05-10
    LuckyPiggie
    Expected unfortunately 
  • JP24
    2022-05-10
    JP24
    Although I currently have shares for this stock counter and am stuck at high prices, I have to sadly say that this stock is finished. During pandemic, not a single vaccine released and now nearing to the end of one major phase of the pandemic, yet not a single vaccine released. Not sure why this company still exists.
  • Lamborghini1
    2022-05-10
    Lamborghini1
    👍
Leave a comment
4